PAPER Beratis IN, Pavlou D, Papadimitriou E, Andronas N, Kontaxopoulou D, Fragkiadaki S, Yannis G, Papageorgiou SG

Mild Cognitive Impairment and driving: Does in-vehicle distraction affect driving performance?

Accid Anal Prev. 2017 Jun;103:148-155. Epub 2017 Apr 22 PubMed.

PAPER Post SG

Why the tolerance of potential harms? Research ethics in Alzheimer disease.

Account Res. 1999;7(2-4):241-53. PubMed.

PAPER Luckmann R

Donepezil improved the clinical state and quality of life in moderate-to-severe Alzheimer disease.

ACP J Club. 2002 Mar-Apr;136(2):59. PubMed.

PAPER Luxenberg JS

Review: selegiline leads to a small short-term improvement in cognition and activities of daily living in Alzheimer disease.

ACP J Club. 2002 Jul-Aug;137(1):10. PubMed.

PAPER Larson E

Galantamine improved cognition and global functioning in vascular dementia or Alzheimer disease with cerebrovascular disease.

ACP J Club. 2002 Nov-Dec;137(3):102. PubMed.

PAPER Hirsch CH

Memantine was better than placebo in Alzheimer disease already being treated with donepezil.

ACP J Club. 2004 Sep-Oct;141(2):38. PubMed.

PAPER Luckmann R

Review: cholinesterase inhibitors may be effective in Alzheimer disease.

ACP J Club. 2006 Jan-Feb;144(1):19. PubMed.

PAPER Hirsch C

Galantamine was effective in mild-to-moderate Alzheimer disease.

ACP J Club. 2006 Sep-Oct;145(2):50. PubMed.

PAPER Larson E, McCurry S

Olanzapine, quetiapine, or risperidone did not differ from placebo for Alzheimer disease.

ACP J Club. 2007 Mar-Apr;146(2):35. PubMed.

PAPER Hirsch C

An exercise program led to a slower decline in activities of daily living in nursing-home patients with Alzheimer disease.

ACP J Club. 2007 Jul-Aug;147(1):5. PubMed.

PAPER Reekum R

Donepezil was no better than placebo for agitation in patients with Alzheimer disease.

ACP J Club. 2008 Mar-Apr;148(2):33. PubMed.

PAPER Seitz DP, Gruneir A, Rochon PA

Second-generation antipsychotics did not improve outcomes and increased costs for patients with Alzheimer disease and psychosis.

ACP J Club. 2008 Mar-Apr;148(2):53. PubMed.

PAPER Chowdhury SR, Balaji SN, Mondal S, Meher N, Trivedi V, Iyer PK

Modulating Early Stage Amyloid Aggregates by Dipeptide-Linked Perylenebisimides: Structure-Activity Relationship, Inhibition of Fibril Formation in Human CSF and Aβ1-40.

ACS Appl Bio Mater. 2018 Aug 20;1(2):403-413. Epub 2018 Jul 23 PubMed.

PAPER Mpambani F, Åslund AK, Lerouge F, Nyström S, Reitan N, Huuse EM, Widerøe M, Chaput F, Monnereau C, Andraud C, Lecouvey M, Handrick S, Prokop S, Heppner FL, Nilsson P, Hammarström P, Lindgren M, Parola S

Two-Photon Fluorescence and Magnetic Resonance Specific Imaging of Aβ Amyloid Using Hybrid Nano-GdF3 Contrast Media.

ACS Appl Bio Mater. 2018 Aug 20;1(2):462-472. Epub 2018 Jul 30 PubMed.

PAPER Chung PJ, Zhang Q, Hwang HL, Leong A, Maj P, Szczygiel R, Dufresne EM, Narayanan S, Adams EJ, Lee KY

α-Synuclein Sterically Stabilizes Spherical Nanoparticle-Supported Lipid Bilayers.

ACS Appl Bio Mater. 2019 Apr 15;2(4):1413-1419. Epub 2019 Mar 11 PubMed.